Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability

Abstract

Objective: To validate the newly developed Multiple Sclerosis Impact Scale (MSIS-29) in a large, well characterized, independent group of MS patients by investigating the relation between the MSIS-29 and the Guy’s Neurological Disability Scale (GNDS), the Expanded Disability Status Scale (EDSS) and the MS Functional Composite (MSFC). Methods: Two hundred MS patients were recruited at our outpatient department. At the same visit GNDS, EDSS, MSFC and MSIS-29 were assessed. Data obtained from GNDS, EDSS and MSFC assessment were compared to both physical and psychological impact scores of the MSIS-29. In addition the contribution of GNDS subcategories, EDSS functional systems and MSFC components to the physical and psychological impact scores of the MSIS-29 was studied. Results: Median scores were 37.5 for the physical and 22.2 for the psychological impact score of the MSIS-29, 13.0 for GNDS and 4.0 for EDSS. Mean MSFC was 0.07. The physical impact score showed good correlations with both GNDS (0.79) and EDSS (0.68) and a moderate correlation with the MSFC (- 0.53). The psychological impact score showed weak correlations with EDSS (0.22) and MSFC (-0.30) and a moderately strong correlation with the GNDS (0.58). In 50 (25%) patients, scores on physical and psychological impact scales diverted, i.e., a relative high score on one scale combined with a relative low score on the other scale. This was related to the clinical disease course. Conclusion: Our study supports the use of the MSIS-29 as a measure for the assessment of physical impact of MS on normal daily life. In addition, our data provides a deeper understanding of the factors that determine both physical and psychological disease impact. Discrepancies between the latter two aspects deserve further attention.

Keywords

disability MS MSIS-29 validation

Get full access to this article

View all access options for this article.

References

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

Cutter GR , Baier ML , Rudick RA , Cookfair DL , Fischer JS , Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure . Brain 1999; 122: 871-882 .

Miller DM. Health-related quality of life . Mult Scler 2002; 8: 269-270 .

Sharrack B , Hughes RA. The Guy’s Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis . Mult Scler 1999; 5: 223-233 .

Hobart J , Lamping D , Fitzpatrick R , Riazi A , Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure . Brain 2001; 124: 962-973 .

Hoenig H , Hoff J , McIntyre L , Branch LG. The self-reported functional measure: predictive validity for health care utilization in multiple sclerosis and spinal cord injury . Arch Phys Med Rehabil 2001; 82: 613-618 .

Schwartz CE , Vollmer T , Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group . Neurology 1999; 52: 63-70 .

Riazi A , Hobart JC , Lamping DL , Fitzpatrick R , Thompson AJ. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples . J Neurol Neurosurg Psychiatry 2002; 73: 701-704 .

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

10.

Lublin FD , Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . Neurology 1996; 46: 907-911 .

11.

Goodkin DE. EDSS reliability . Neurology 1991; 41: 332-332 .

12.

Kalkers NF , de Groot V , Lazeron RH , Killestein J , Ader HJ , Barkhof F et al. MS functional composite: relation to disease phenotype and disability strata . Neurology 2000; 54: 1233-1239 .

13.

Cohen JA , Fischer JS , Bolibrush DM , Jak AJ , Kniker JE , Mertz LA et al. Intrarater and interrater reliability of the MS functional composite outcome measure . Neurology 2000; 54: 802-806 .

14.

Hoogervorst ELJ , van Winsen LM , Eikelenboom MJ , Kalkers NF , Uitdehaag BMJ , Polman CH. Comparisons of patient self-report, neurologic examination, and functional impairment in MS . Neurology 2001; 56: 934-937 .

15.

Sharrack B , Hughes RA. Scale development and Guy’s Neurological Disability Scale . J Neurol 1999; 246: 226-226 .

16.

Rudick R , Antel J , Confavreux C , Cutter G , Ellison G , Fischer J et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 1997; 42: 379-382 .

17.

Rudick R , Antel J , Confavreux C , Cutter G , Ellison G , Fischer J et al. Clinical outcomes assessment in multiple sclerosis . Ann Neurol 1996; 40: 469-479 .

18.

McHorney CA , Ware JE Jr , Raczek AE. The MOS-36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs . Med Care 1993; 31: 247-263 .